Coagulation and fibrinolysis balance in disseminated intravascular coagulation.
blood coagulation
disseminated intravascular coagulation
fibrinolysis
hemostatic monitoring
sepsis
Journal
Pediatrics international : official journal of the Japan Pediatric Society
ISSN: 1442-200X
Titre abrégé: Pediatr Int
Pays: Australia
ID NLM: 100886002
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
revised:
01
02
2021
received:
13
11
2020
accepted:
02
03
2021
pubmed:
5
3
2021
medline:
23
11
2021
entrez:
4
3
2021
Statut:
ppublish
Résumé
Sepsis is a common underlying disease associated with disseminated intravascular coagulation (DIC). We have recently determined hemostatic pathological states at diagnosis through simultaneous assessment of coagulation and fibrinolysis potentials in sepsis-associated DIC using clot-fibrinolysis waveform analysis. Here we aimed to investigate hemostatic pathological states, focusing on the balance between coagulation and fibrinolysis dynamics during the clinical course in pediatric sepsis-associated DIC. Coagulation and fibrinolysis potential functions in three pediatric patients with sepsis-associated DIC during their clinical course were quantified using clot-fibrinolysis waveform analysis. A maximum coagulation velocity (|min1|) and maximum fibrinolysis velocity (|FL-min1|) was calculated as a ratio relative to normal plasma. In case 1, coagulation-enhanced and fibrinolysis-depressed state (|min1|-ratio 2.22 and |FL-min1|-ratio 0.42) was observed on day 1. This discrepancy significantly reduced after anticoagulant therapy and plasma exchange on day 2. A well-balanced hemostatic state (0.70 and 0.62, respectively) was restored on day 7. In case 2, fibrinolysis-impaired state (|min1|-ratio 1.09 and |FL-min1|-ratio 0.21) was seen on day 1. The |min1| ratio was slightly prolonged and the |FL-min1| ratio was severely decreased. Both were restored on day 7 and returned to normal levels on day 12. In case 3, twofold coagulation- and fibrinolysis-enhanced states (|min1|-ratio 1.99 and |FL-min1|-ratio 1.11) were seen on day 1. However, both potentials rapidly decreased on day 2 (0.49 and 0.0, respectively). She died on day 5. The hemostatic pathological states in sepsis-associated DIC depend on disease progression. Comprehensive assessment of coagulation-fibrinolysis potentials over time may therefore be helpful in considering optimal treatment plans for sepsis-associated DIC.
Sections du résumé
BACKGROUND
BACKGROUND
Sepsis is a common underlying disease associated with disseminated intravascular coagulation (DIC). We have recently determined hemostatic pathological states at diagnosis through simultaneous assessment of coagulation and fibrinolysis potentials in sepsis-associated DIC using clot-fibrinolysis waveform analysis. Here we aimed to investigate hemostatic pathological states, focusing on the balance between coagulation and fibrinolysis dynamics during the clinical course in pediatric sepsis-associated DIC.
METHODS
METHODS
Coagulation and fibrinolysis potential functions in three pediatric patients with sepsis-associated DIC during their clinical course were quantified using clot-fibrinolysis waveform analysis. A maximum coagulation velocity (|min1|) and maximum fibrinolysis velocity (|FL-min1|) was calculated as a ratio relative to normal plasma.
RESULTS
RESULTS
In case 1, coagulation-enhanced and fibrinolysis-depressed state (|min1|-ratio 2.22 and |FL-min1|-ratio 0.42) was observed on day 1. This discrepancy significantly reduced after anticoagulant therapy and plasma exchange on day 2. A well-balanced hemostatic state (0.70 and 0.62, respectively) was restored on day 7. In case 2, fibrinolysis-impaired state (|min1|-ratio 1.09 and |FL-min1|-ratio 0.21) was seen on day 1. The |min1| ratio was slightly prolonged and the |FL-min1| ratio was severely decreased. Both were restored on day 7 and returned to normal levels on day 12. In case 3, twofold coagulation- and fibrinolysis-enhanced states (|min1|-ratio 1.99 and |FL-min1|-ratio 1.11) were seen on day 1. However, both potentials rapidly decreased on day 2 (0.49 and 0.0, respectively). She died on day 5.
CONCLUSIONS
CONCLUSIONS
The hemostatic pathological states in sepsis-associated DIC depend on disease progression. Comprehensive assessment of coagulation-fibrinolysis potentials over time may therefore be helpful in considering optimal treatment plans for sepsis-associated DIC.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1311-1318Subventions
Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : 18K15726
Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : 18K07885
Organisme : Special Project Grant at Nara Medical University
Informations de copyright
© 2021 Japan Pediatric Society.
Références
Semeraro N, Ammollo CT, Semeraro F, Colucci M. Sepsis-associated disseminated intravascular coagulation and thromboembolic disease. Mediterr. J. Hematol.. Infect. Dis. 2010; 2: e2010024.
Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb. Haemost. 2001; 86: 1327-30.
Levi M. Current understanding of disseminated intravascular coagulation. Br. J. Haematol. 2004; 124: 567-76.
Levi M. The coagulant response in sepsis. Clin. Chest Med. 2008; 29: 627-42.
Semeraro N, Colucci M. Changes in the coagulation-fibrinolysis balance of endothelial cells and mononuclear phagocytes: Role in disseminated intravascular coagulation associated with infectious diseases. Int. J. Clin. Lab. Res. 1992; 21: 214-20.
Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravenous coagulation. Br. J. Haematol. 2009; 145: 24-33.
Iba T, Asakura H. Comparison between British and Japanese guidelines for the diagnosis and treatment of disseminated intravascular coagulation. Br. J. Haematol. 2010; 149: 461-2.
Nishida O, Ogura H, Egi M et al. The Japanese Clinical Practice Guidelines for management of sepsis and septic shock 2016 (J-SSCG 2016). Acute Med. Surg. 2018; 5: 3-89.
Kienast J, Juers M, Wiedermann CJ et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J. Thromb. Haemost. 2006; 4: 90-7.
Saito H, Maruyama I, Shimazaki S et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: Results of a phase III, randomized, double-blind clinical trial. J. Thromb. Haemost. 2007; 5: 31-41.
Gando S, Saitoh D, Ishikura H et al. A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Crit. Care. 2013; 17: R297.
Yamakawa K, Aihara M, Ogura H, Yuhara H, Hamasaki T, Shimazu T. Recombinant human soluble thrombomodulin in severe sepsis: A systematic review and meta-analysis. J. Thromb. Haemost. 2015; 13: 508-19.
Nogami K, Matsumoto T, Sasai K, Ogiwara K, Arai N, Shima M. A novel simultaneous clot-fibrinolysis waveform analysis for assessing fibrin formation and clot lysis in haemorrhagic disorders. Br. J. Haematol. 2019; 187: 518-29.
Onishi T, Nogami K, Ishihara T et al. A pathological clarification of sepsis-associated disseminated intravascular coagulation based on comprehensive coagulation and fibrinolysis function. Thromb. Haemost. 2020; 120: 1257-69.
British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br. J. Haematol. 2003; 122: 10-23.
Mueller MM, Bomke B, Seifried E. Fresh frozen plasma in patients with disseminated intravascular coagulation or in patients with liver diseases. Thromb. Res. 2002; 107(Suppl 1): S9-17.
Asakura H. Classifying types of disseminated intravascular coagulation: clinical and animal models. J. Intensive Care. 2014; 6: 20.
Asakura H, Jokaji H, Saito M et al. Changes in plasma levels of tissue-plasminogen activator/inhibitor complex and active plasminogen activator inhibitor in patients with disseminated intravascular coagulation. Am. J. Hematol. 1991; 36: 176-83.
Rea CJ, Sorensen B, Ingerslev J et al. Fibrinogen: A procoagulant and an anticoagulant. Blood 2011; 118: 384.
Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin. Immunopathol. 2012; 34: 43-62.
Asakura H, Jokaji H, Saito M et al. Study of the balance between coagulation and fibrinolysis in disseminated intravascular coagulation using molecular markers. Blood Coagul. Fibrinolysis. 1994; 5: 829-32.
Takahashi H, Tatewaki W, Wada K, Hanano M, Shibata A. Thrombin vs plasmin generation in disseminated intravascular coagulation associated with various underlying disorders. Am. J. Hematol. 1990; 33: 90-5.
Kario K, Matsuo T, Kodama K, Matsuo M, Yamamoto K, Kobayashi H. Imbalance between thrombin and plasmin activity in disseminated intravascular coagulation. Assessment by the thrombin-antithrombin-III complex/plasmin-alpha-2-antiplasmin complex ratio. Haemostasis. 1992; 22: 179-86.
Mair G, Dunhill S, Tiplady C. Prognostic implications of a biphasic waveform for APTT analysis in a district general hospital. Int. J. Lab. Hematol. 2008; 30: 467-72.
Toh CH, Giles AR. Waveform analysis of clotting test optical profiles in the diagnosis and management of disseminated intravascular coagulation (DIC). Clin. Lab. Haem. 2002; 24: 321-7.
Toh CH, Samis J, Downey C. Biphasic transmittance waveform in the APTT coagulation assay is due to the formation of a Ca2+-induced complex of C-reactive protein with very low density lipoprotein and is a novel marker of impending disseminated intravascular coagulation. Blood 2002; 100: 2522-9.
Downey C, Kazmi R, Toh CH. Early identification and prognostic implications in disseminated intravascular coagulation through transmittance waveform analysis. Thromb. Haemost. 1998; 80: 65-9.
Asakura H, Suga Y, Yoshida T et al. Pathophysiology of disseminated intravascular coagulation (DIC) progresses at a different rate in tissue factor-induced and lipopolysaccharide-induced DIC models in rats. Blood Coagul. Fibrinolysis. 2003; 14: 221-8.
Hayakawa M, Gando S, Ieko M et al. Massive amounts of tissue factor induce fibrinogenolysis without tissue hypoperfusion in rats. Shock. 2013; 39: 514-9.
Ishihara T, Nogami K, Onishi T et al. Hemostatic function in hyperfibrinolytic disseminated intravascular coagulation. Pediatr. Int. 2019; 61: 872-81.